GHRP-2: Research & Evidence
Established EvidencePublished research, clinical trial data, and evidence grading for GHRP-2 across studied indications.
Back to GHRP-2 overviewResearch Summary
GHRP-2 (pralmorelin) has actual regulatory approval in Japan for diagnostic testing of GH deficiency and 3-5 RCTs in humans — making it the most clinically validated GHRP. It has never received FDA approval in the US and remains WADA-prohibited since 2008.
Evidence by Indication (2 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Growth hormone secretion | Tier B | 8 | Potent GH secretagogue with well-characterized dose-response in clinical studies |
| Appetite stimulation | Tier C | 2 | Stimulates ghrelin receptor, increasing appetite — potential in cachexia |
Graded using our evidence tier methodology.
Citations (7 sources)
- 1. Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy. Review
(2022), Journal of pain & palliative care pharmacotherapy
- 2. The effect of growth hormone releasing peptide-2 on upper gastrointestinal contractile activity and food intake in conscious dogs. Study
(2009), Journal of gastroenterology
- 3. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Study
(2005), American journal of physiology. Endocrinology and metabolism
- 4. Pralmorelin testing for growth hormone deficiency. Clinical Trial
Kojima M, et al. (2004), Endocrine Journal
- 5. Growth hormone-releasing peptide-2 reduces inward rectifying K+ currents via a PKA-cAMP-mediated signalling pathway in ovine somatotropes. Study
(2002), The Journal of physiology
- 6. GH-releasing effect of GHRP-2. Clinical Trial
Hashimoto K, et al. (2002), Clinical Endocrinology
- 7. Growth hormone responses during strenuous exercise: the role of GH-releasing hormone and GH-releasing peptide-2. Study
(2000), Medicine and science in sports and exercise